{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:17:24Z","timestamp":1784614644447,"version":"3.55.0"},"reference-count":74,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2009,1,29]],"date-time":"2009-01-29T00:00:00Z","timestamp":1233187200000},"content-version":"vor","delay-in-days":639,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2007,5]]},"abstract":"<jats:sec><jats:title>Background and purpose:<\/jats:title><jats:p>F15063 is a high affinity D<jats:sub>2<\/jats:sub>\/D<jats:sub>3<\/jats:sub>antagonist, D<jats:sub>4<\/jats:sub>partial agonist, and high efficacy 5\u2010HT<jats:sub>1A<\/jats:sub>agonist, with little affinity (40\u2010fold lower than for D<jats:sub>2<\/jats:sub>receptors) at other central targets. Here, the profile of F15063 was evaluated in models of positive symptoms of schizophrenia and motor side\u2010effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental approach:<\/jats:title><jats:p>Rodent behavioural tests were based on reversal of hyperactivity induced by psychostimulants and on measures of induction of catalepsy and \u2018serotonin syndrome\u2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key results:<\/jats:title><jats:p>F15063 potently (ED<jats:sub>50<\/jats:sub>s: 0.23 to 1.10 mg kg<jats:sup>\u22121<\/jats:sup>i.p.) reversed methylphenidate\u2010induced stereotyped behaviors, blocked d\u2010amphetamine and ketamine hyperlocomotion, attenuated apomorphine\u2010induced prepulse inhibition (PPI) deficits, and was active in the conditioned avoidance test. In mice, it reversed apomorphine\u2010induced climbing (ED<jats:sub>50<\/jats:sub>= 0.30 mg kg<jats:sup>\u22121<\/jats:sup>i.p.). F15063, owing to its 5\u2010HT<jats:sub>1A<\/jats:sub>agonism, did not produce (ED<jats:sub>50<\/jats:sub>&gt; 40 mg kg<jats:sup>\u22121<\/jats:sup>i.p.) catalepsy in rats and mice, a behavior predictive of occurrence of extra\u2010pyramidal syndrome (EPS) in man. This absence of cataleptogenic activity was maintained upon sub\u2010chronic treatment of rats for 5 days at 40 mg kg<jats:sup>\u22121<\/jats:sup>p.o. Furthermore, F15063 did not induce the \u2018serotonin syndrome\u2019 in rats (flat body posture and forepaw treading: ED<jats:sub>50<\/jats:sub>&gt;32 mg kg<jats:sup>\u22121<\/jats:sup>i.p.).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and implications:<\/jats:title><jats:p>F15063 conformed to the profile of an atypical antipsychotic, with potent actions in models of hyperdopaminergic activity but without inducing catalepsy. These data suggest that F15063 may display potent antipsychotic actions with low EPS liability. This profile is complemented by a favourable profile in rodent models of negative symptoms and cognitive deficits of schizophrenia (companion paper).<\/jats:p><jats:p><jats:italic>British Journal of Pharmacology<\/jats:italic>(2007)<jats:bold>151<\/jats:bold>, 253\u2013265. doi:<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"doi\" xlink:href=\"10.1038\/sj.bjp.0707159\">10.1038\/sj.bjp.0707159<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1038\/sj.bjp.0707159","type":"journal-article","created":{"date-parts":[[2007,3,20]],"date-time":"2007-03-20T16:55:01Z","timestamp":1174409701000},"page":"253-265","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["F15063, a compound with D<sub>2<\/sub>\/D<sub>3<\/sub>antagonist, 5\u2010HT<sub>1A<\/sub>agonist and D<sub>4<\/sub>partial agonist properties: (II) Activity in models of positive symptoms of schizophrenia"],"prefix":"10.1111","volume":"151","author":[{"given":"R","family":"Depoort\u00e8re","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M S","family":"Kleven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Prinssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Colpaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Vacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Newman\u2010Tancredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,29]]},"reference":[{"issue":"4","key":"e_1_2_8_2_1","first-page":"5432","article-title":"F15063, a novel antipsychotic with dopamine D2\/D3 antagonist, 5\u2010HT1A agonist and D4 partial agonist properties: III) Duration of brain D2\u2010like receptor occupancy, antipsychotic\u2010like activity and plasma concentration in rodents","volume":"16","author":"Assie MB","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301015"},{"issue":"1","key":"e_1_2_8_4_1","first-page":"P01.167","article-title":"Comparative analysis of typical, atypical, and novel antipsychotics with preferential D2\/D3 and 5\u2010HT1A affinity in rodent models of cognitive flexibility and sensory gating: (II) The reversal learning task and PPI of the startle reflex","volume":"9","author":"Auclair A","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110101500108"},{"key":"e_1_2_8_6_1","article-title":"Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2\/serotonin 5\u2010HT1a activity: comparison with typical and atypical conventional antipsychotics","author":"Bardin L","journal-title":"Behav Pharmacol"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300940"},{"issue":"1","key":"e_1_2_8_8_1","first-page":"P01.166","article-title":"Comparative analysis of typical, atypical, and novel antipsychotics with preferential D2\/D3 and 5\u2010HT1A affinity in rodent models of cognition and memory deficits: (I) The hole\u2010board and the social recognition tests","volume":"9","author":"Bardin L","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-003-0094-7"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv-6-4-564"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90344-6"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.10.1829"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(02)01643-8"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2004.02.008"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8986.1978.tb01390.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.151.1.20"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174869"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.01.027"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/ajp.155.6.751","article-title":"Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome","volume":"155","author":"Buchanan RW","year":"1998","journal-title":"Am J Psychiatry"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.6.1035"},{"key":"e_1_2_8_21_1","first-page":"252","article-title":"The therapeutic role of 5\u2010HT1A and 5\u2010HT2A receptors in depression","volume":"29","author":"Celada P","year":"2004","journal-title":"Rev Psychiatry Neurosci"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(97)00176-0"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300262"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2006.01.051"},{"key":"e_1_2_8_25_1","article-title":"F15063 a compound with D2\/D3 antagonist, 5\u2010HT1A agonist and D4 partial agonist properties: (III) Activity in models of cognition and negative symptoms","author":"Depoort\u00e8re R","year":"2007","journal-title":"Br J Pharmacol"},{"issue":"1","key":"e_1_2_8_26_1","first-page":"P01.165","article-title":"F15063, an innovative antipsychotic with D2\/D3 antagonist, 5\u2010HT1A agonist and D4 partial agonist properties: (II) Behavioural profile in models of positive, negative symptoms and cognitive deficits of schizophrenia","volume":"9","author":"Depoort\u00e8re R","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300261"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245588"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2999-05.2005"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-894X(01)00425-5"},{"key":"e_1_2_8_31_1","first-page":"237","article-title":"New approaches for psychosis treatment: design, synthesis and SAR of ligands binding to dopamine D2 and serotonin 5\u2010HT1A receptors. Drugs of the future","volume":"27","author":"Feenstra RW","year":"2002","journal-title":"XVIIth International Symposium on Medicinal Chemistry"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035458"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988119901300111"},{"key":"e_1_2_8_34_1","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002130050165","article-title":"Blockade of phencyclidine\u2010induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice","volume":"129","author":"Gleason SD","year":"1997","journal-title":"Psychopharmacology"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199106000-00008"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00174066"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2004.06.023"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00154.x"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02346-X"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3908(88)90134-7"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.153.4.466"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01251-3"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2005.02.005"},{"key":"e_1_2_8_44_1","first-page":"181","article-title":"Inhibition of methylphenidate\u2010induced behaviors in rats: differences among neuroleptics","volume":"267","author":"Koek W","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_45_1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0022-3565(24)37788-2","article-title":"F 11440, a potent, selective, high efficacy 5\u2010HT1A receptor agonist with marked anxiolytic and antidepressant potential","volume":"287","author":"Koek W","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00439547"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01277672"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-977X(02)80374-1"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0893-133X(98)00072-4"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00858.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)01445-3"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199306000-00009"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707158"},{"issue":"1","key":"e_1_2_8_54_1","first-page":"P01.164","article-title":"F15063, an innovative antipsychotic with D2\/D3 antagonist, 5\u2010HT1A agonist and D4 partial agonist properties: (I) in vitro, neurochemical and neuroendocrine profiles","volume":"9","author":"Newman\u2010Tancredi A","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050124"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200006000-00013"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1177\/026988110201600301"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.03.019"},{"issue":"10","key":"e_1_2_8_59_1","first-page":"514","article-title":"Receptor pharmacology of neuroleptics: relation to clinical effects","volume":"60","author":"Richelson E","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(00)00850-7"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)81951-6"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.1.88"},{"key":"e_1_2_8_63_1","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0893-133X(99)00057-3","article-title":"Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5\u2010HT1A receptor activation","volume":"21","author":"Sprouse JS","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.10.1722"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-200006000-00019"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008877-200006000-00002"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(86)90005-3"},{"key":"e_1_2_8_68_1","volume-title":"Manual of Pharmacological Calculations with Computer Programs","author":"Tallarida RJ","year":"1987"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(93)90242-6"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-005-2268-5"},{"key":"e_1_2_8_71_1","unstructured":"VacherB CuisiatS KoekW ColpaertF(2002).3\u2010(Cyclopenten\u20101\u2010yl)\u2010benzyl\u2010or 3\u2010(Cyclopenten\u20101\u2010yl)\u2010heteroarylmethyl\u2010amine derivatives and use thereof as medicines for treating schizophrenia. Patent # WO 2004\/035561 A1. Priority 16 October 2002."},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244451"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000466"},{"key":"e_1_2_8_74_1","first-page":"72","article-title":"DU\u2010127090 Solvay\/H Lundbeck","volume":"4","author":"Wolf W","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(99)80690-7"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0707159","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Fsj.bjp.0707159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/sj.bjp.0707159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T04:11:04Z","timestamp":1736914264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1038\/sj.bjp.0707159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,5]]}},"alternative-id":["10.1038\/sj.bjp.0707159"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjp.0707159","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,5]]},"assertion":[{"value":"2009-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}